EUVIMEDEUVIMED entdecken
Open Access

Characteristics of Immune Checkpoint Inhibitor (ICI)-Related Hepatotoxicity Based on the Baseline Liver Function

Won-Jung Jung, Eun-Jung Jo, Ye-Jee Kim, Mihyun Park, Eunji Kim, Yu-Seon Jung, Sook Ryun Park, Ji Seon Oh, So-Hui Kim, Jeongbin Park, Sun-Young Jung, Nakyung Jeon

Cancer Research and Treatment · 2025

DOI: 10.4143/crt.2025.040 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Research and Treatment, 2025. Verfasst von Won-Jung Jung und 11 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy and Research Institute for Drug Development, Pusan National University, Busan, Korea. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Chemical and Drug Induced Liver Injury, Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Korean Institute of Drug Safety and Risk Management, Pusan National University Hospital, Ministry of Health and Welfare.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: This study estimated the incidence of immune checkpoint inhibitor-related hepatotoxicity (ICH), identified risk factors, and characterized patients who developed ICH. MATERIALS AND METHODS: Adult patients treated with immune checkpoint inhibitors (ICIs) from January 2015 to June 2022 in a tertiary hospital were included, excluding those without liver function tests or those with liver cancer but normal baseline liver function. Patients were stratified by baseline liver function status; in overall and each of stratified cohorts ICH incidence was calculated as the number of events per 100 person-years with grade 3 hepatotoxicity as the primary outcome. Patient characteristics were assessed using descriptive statistics, and risk factors were identified through multivariable Cox regression. Causality between ICI use and hepatotoxicity was assessed using the Naranjo Algorithm. RESULTS: Among 803 patients, the ICH incidence was 19.5 cases per 100 person-years, with a higher incidence (47.3 vs. 9.3 cases per 100 person-years) and earlier onset (13 vs. 15 days) in the abnormal compared to the normal group. Significant risk factors for ICH included female sex in the normal group and liver cancer in the abnormal group. According to the Naranjo Algorithm, all the 60 ICH cases were classified as "probable" or "possible". Among the 60 cases, 61.7% (n=37) resulted in ICI discontinuation. The baseline liver function did not impact on the severity or the likelihood of ICI discontinuation. CONCLUSION: Future studies are needed to evaluate whether the impact of ICI discontinuation on survival outcomes in patients with ICH varies based on baseline liver function abnormalities.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immune Checkpoint InhibitorsChemical and Drug Induced Liver InjuryNeoplasmsHumansFemaleMaleMiddle AgedIncidenceRisk FactorsAgedLiver Function TestsLiverAdultLiver NeoplasmsRetrospective Studies

Stichwörter der Autor:innen

Causality assessmentHepatotoxicityImmune checkpoint inhibitors

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • College of Pharmacy and Research Institute for Drug Development, Pusan National University, Busan, Korea.
  • Department of Internal Medicine, School of Medicine, Pusan National University, Busan, Korea.
  • Department of Clinical Epidemiology and Biostatistics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
  • College of Pharmacy and Department of Global Innovative Drugs, Chung-Ang University, Seoul, Korea.
  • College of Pharmacy, Chung-Ang University, Seoul, Korea.
  • Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.

Förderung

  • Korean Institute of Drug Safety and Risk Management
  • Pusan National University Hospital
  • Ministry of Health and Welfare
  • Korea Health Information Service

Zitieren

APA

Jung, W. J., Jo, E. J., Kim, Y. J., Park, M., Kim, E., Jung, Y. S., Park, S. R., Oh, J. S., Kim, S. H., Park, J., Jung, S. Y., & Jeon, N. (2025). Characteristics of Immune Checkpoint Inhibitor (ICI)-Related Hepatotoxicity Based on the Baseline Liver Function. Cancer Research and Treatment. https://doi.org/10.4143/crt.2025.040

Vancouver

Jung WJ, Jo EJ, Kim YJ, Park M, Kim E, Jung YS, et al. Characteristics of Immune Checkpoint Inhibitor (ICI)-Related Hepatotoxicity Based on the Baseline Liver Function. Cancer Research and Treatment. 2025. doi:10.4143/crt.2025.040

BibTeX
@article{Jung2025,
  author = {Jung, Won-Jung and Jo, Eun-Jung and Kim, Ye-Jee and Park, Mihyun and Kim, Eunji and Jung, Yu-Seon and Park, Sook Ryun and Oh, Ji Seon and Kim, So-Hui and Park, Jeongbin and Jung, Sun-Young and Jeon, Nakyung},
  title = {Characteristics of Immune Checkpoint Inhibitor (ICI)-Related Hepatotoxicity Based on the Baseline Liver Function},
  journal = {Cancer Research and Treatment},
  year = {2025},
  doi = {10.4143/crt.2025.040}
}
Kostenlos starten →